Cargando…
Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
PURPOSE: Rituximab (R) or obinutuzumab (G) combined with CHOP chemotherapy are used in previously untreated follicular lymphoma (FL). The aim is to compare in real life setting the efficacy and safety of these therapeutic strategies and assess the economic impact of introducing G. METHODS: This retr...
Autores principales: | Claustre, Gwladys, Boulanger, Coralie, Maloisel, Frédéric, Etienne-Selloum, Nelly, Fornecker, Luc-Matthieu, Durot, Eric, Slimano, Florian, Graff, Véronique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255466/ https://www.ncbi.nlm.nih.gov/pubmed/35789429 http://dx.doi.org/10.1007/s00432-022-04155-2 |
Ejemplares similares
-
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017) -
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021) -
Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013) -
Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017) -
The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)